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ABSTRACT
AQUEOUS RAFT POLYMERIZATION OF GLYCOPOLYMERS FOR PEPTIDE
INTERACTION STUDIES AND ANTIMICROBIAL PEPTIDE MIMICS FOR
ANTIMICROBIAL ACTIVITY AND SELECTIVITY STUDIES
by Sarah Elizabeth Exley
May 2015
The first section of this work describes the synthesis and characterization of novel
glycopolymers synthesized to model GM1 gangliosides, a glycolipid found in neuronal
cells. Glucose and galactose were attached to N-hydroxyethyl acrylamide, using
chemistry that granted control over the stereochemistry at the C1’ carbon of each
saccharide, and polymerized via aqueous RAFT (aRAFT). Homopolymers, targeting
either 30 or 300 DP, and copolymers, with N-dimethyl acrylamide, were prepared as a
glycopolymer platform for investigation of amyloid β (Aβ), a naturally occurring peptide
associated with Alzheimer’s disease, aggregation. Aβ aggregation kinetics and aggregate
size in the presence of glycopolymer were determined.
The second section of this work describes N-(3-guanadinopropyl)methacrylamide
(GPMA) synthesis, homopolymerization and copolymerization with N-(3-aminopropyl)
methacrylamide (APMA) using aRAFT. Many naturally occurring AMPs have an
abundance of lysine and arginine. GPMA, an arginine mimic, was incorporated into our
established acrylamide based antimicrobial peptide (AMP) platform with APMA, a lysine
mimic, to increase the activity and selectivity of our AMPs over a wider range of
bacteria. Antimicrobial activity, against E. coli, S. aureus, and P. aeruginosa, and
selectivity, against human red blood cells and cancer cells, was determined for the
ii

GPMA and APMA homopolymers and copolymers. The effect of GPMA counterion on
activity and selectivity was also investigated.
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CHAPTER I
INTRODUCTION
This dissertation focuses on the synthesis and testing of polymers that mimic
GM1 gangliosides and antimicrobial peptides. In Chapters II and III, the attachment of
glucose and galactose to an acrylamide backbone, with specific β stereochemistry at C1’,
will be described. The homopolymerization and copolymerization, with N, Ndimethylacrylamide, of the synthesized glucose and galactose monomers using aqueous
RAFT polymerization will also be discussed. Aggregation of amyloid β peptides in the
presence of the reported polymers will be conferred. Chapters IV and V will investigate
the synthesis of a methacrylamide monomer with a guanidinium pendant group. This
monomer as well as a methacrylamide with a primary amine will be polymerized into
homopolymers and statistical copolymers via aqueous RAFT polymerization. These
polymers will then be tested for effective bacterial activity and selectivity.
Aqueous RAFT (aRAFT) will be used to synthesize polymers with precise
molecular weights and compositions to allow systematic investigations. aRAFT is an
ideal technique for the development of saccharide- and amine-containing polymers with
specific distributions, as it is compatible with a wide range of monomers, enables control
of molecular weight and polydispersity, allows for a wide range of polymer
conformations to be synthesized, and does not require extreme protection/deprotection of
substituent groups. Additionally, aRAFT can be performed under aqueous conditions
and, unlike other controlled polymerization techniques, is unaffected by charged species,
maintaining control throughout the reaction.
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In both projects, either an acrylamide or methacrylamide is utilized as the
polymer backbone. This was done to impart the desirable chemical attributes of
acrylamides/methacrylamides onto our synthetic platforms. Specifically, we designed
polymers with acrylamide backbones to increase their hydrolytic stability and solubility.
The antimicrobial peptide testing was done at physiological pH (pH 7.4); however, the
Aβ investigation was done at pH 8, and the increased stability and solubility of the
acrylamide backbone eliminates hydrolysis and precipitation concerns, respectively.
Additionally, both projects are designed as platforms for future research, therefore,
having an acrylamide/methacrylamide backbone will allow for a more diverse
implementation of the developed systems.
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CHAPTER II
GLYCOPOLYMER ARCHITECTURES
Chapter Overview
This chapter aims to inform the reader of pertinent literature pertaining to the
aggregation of amyloid β (Aβ) peptides in response to the saccharides of GM1
gangliosides, providing the argument and need for the research presented in Chapter III.
Briefly, Aβ peptides are implicated in the pathology of Alzheimer’s disease, as they are
present in the extracellular space of neuronal cells as soluble oligomers or insoluble
fibrils that lead to plaque formation. Through interaction with various modulators, Aβ
peptides are shown to undergo conformational change and aggregate into toxic species.
GM1 gangliosides are reported as modulators that increase and alter Aβ aggregation. The
head group of GM1 gangliosides are comprised of several saccharide residues, including
glucose and galactose. Efforts have been made to identify the specific influence of
glucose and galactose on Aβ aggregation; however, it is difficult to separate the effects of
the individual saccharides using traditional biochemical techniques. Circumventive
methods, used to evaluate saccharide contribution, resulted in conflicting reports.
Finally, polymer research has not demonstrated soluble biorelevant glycopolymers that
are stable over a wide range of testing conditions nor used them to evaluate saccharide
impact on Aβ aggregation.
Important Literature
Alzheimer’s disease (AD) is a neurodegenerative disease that is responsible for
approximately 70% of all dementia cases.1 Elucidation of the pathology of AD is
important as it will provide the opportunity for treatment development. AD is
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characterized by the progressive degeneration of cognitive and ambulatory abilities and
the development of intricate neuropatholo
neuropathological features,2 namely significant loss of
neurons and the appearance of senile plaques and neurofibrillary tangles (NFTs).3 The
senile plaques are formed from amyloid fibrils, which are a result of the aggregation of
the peptide amyloid-β (Aβ
Aβ). Aβ is expressed in the extracellular space of the brain and
originate from cleavage of the amyloid precursor protein (APP). The most prevalent
peptides are Aβ40
40 and Aβ
Aβ42,
42, having 40 and 42 amino acid residues, respectively (Figure
1).4 Aβ42 is thought to be the more toxic of the species, and is thus the focus of the
present study.3-4 Aβ aggregates via self
self-association in a nucleation-dependent
dependent manner to
form larger molecular weight oligomers and fibrils.

Figure 1. Illustrations detailing the amino acid residues and their corresponding polarity
or charge of Aβ monomer. Hydrogen bonding occurs at residues 22, glutamic acid, and
28, lysine, stabilizing the monomer in a β sheet conformation.
Various studies have determined that the soluble oligomeric species of Aβ
peptides are the result off an aggregation pathway discrete from that of fibrillogenesis or
amyloidogenesis. Gellerman et al. determined that not only are the pathways discrete,
but interchange between the two aggregate species does not occur, indicating that each
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are stable entities.2 Previous studies in our laboratories demonstrated a similar
phenomenon, indicating that two different aggregation pathways exist.5 Each aggregate
species promotes further conformational change and aggregation of monomeric Aβ42
(i.e. like promotes like).2
The toxicity of Aβ fibrils are widely debated as there seems to be a
disproportionate association between the appearance of fibril plaques and the extent of
neurological damage. That is, the brains of people suffering from AD impairment have
varying concentrations of fibril plaques, and the plaque level does not directly correlate
with the degree of impairment.5 Additionally, Williams et al. determined that the greater
the degree of association of the peptide, meaning the more fibril-like it became, the less
effective it was as a membrane disruptor, with membrane disruption being one potential
cause of neuronal cell death.2 This lack of correlation suggests that the oligomeric
species play a significant role in AD pathology.
Various modulators have been demonstrated to promote conformational changes
and aggregation of Aβ peptides. Gangliosides are glycosphingolipids that are composed
of a hydrophobic ceramide, consisting of a sphingosine and a fatty acid moiety,
hydrophilic sugars and sialic acid moieties (Figure 2).3 Gangliosides are found
throughout the brain in varying concentrations. The fraction of GM1 gangliosides has
been reported to comprise 0.5-13% w/w of the membrane. With increasing age, the GM1
fraction increases to 15-30% w/w of the membrane. Additionally, cholesterol
concentrations in the cell membrane increase with age and promote aggregation and lipid
raft formation of GM1 gangliosides. Increase in ganglioside concentration, both locally
through lipid rafts and globally through increased ganglioside number, is thought to
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promote the shift of common non-toxic monomeric Aβ species to toxic aggregate
species.6 Yanagisawa et al. discovered that GM1-bound Aβ peptides are present during
early stages of AD pathogenesis and it is hypothesized that the peptides act as “seeds” to
polymerize Aβ into mature fibrils and senile plaques.7 Choo-Smith et al. observed that
Aβ40 interacted with micellar GM1-gangliosides and as a result of the interaction, Aβ40
underwent a conformational change characterized by a conformational change from
randomly coiled to cross β-sheet structure.8 The hydrophobic, apolar C-terminal region
of Aβ40 was suggested to be paramount for interaction with GM1-gangliosides. The
authors hypothesized that Aβ interaction with gangliosides could induce membrane
perturbation that ultimately leads to neuronal cell death.8-9 Recently, however,
Yamamoto et al. determined that different variants of Aβ peptides bind to different types
of gangliosides;10 though, the reason has yet to be fully understood. The primary
differences between the various types of gangliosides are the types and distributions of
saccharides present in the hydrophilic head group and the number of sialic acid moieties
present. Sialic acids have been extensively studied and their affects are known.11
Therefore, the preferential binding of the variant Aβ peptides to specific gangliosides
must result from the different types and distributions of saccharides present within each
respective ganglioside.
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Figure 2. An illustration of GM1 ganglioside, with all components appropriately labelled.
To date, little has been accomplished to elucidate the influence of individual
saccharides on the aggregation mechanisms of A
Aβ42. Fung et al. studied the effect of
simple carbohydrates on the aggregation and fibrillogenesis of A
Aβ42
42 by observing
secondary and quaternary conformational changes in relation to the presence of
individual saccharides.12 They concluded that the secondary structure was affected by
glucose and sucrose and that the hydrogen bonding pattern unique to each saccharide is
crucial in the development of A
Aβ42 structure. Matsumoto et al. analyzed saccharidesaccharide
Aβ42
42 binding affinities as well as saccharide
saccharide-induced
induced peptide conformational change and
aggregation through the development of self
self-assembled
assembled monolayers (SAMs)
(SAM of
saccharides, which were entitled sugar microarrays.13 The various saccharides, including
N-acetyl-β-D-glucosamine
glucosamine ((β-GlcNAc), β-galactose (β-Gal), α-mannose
mannose (α-Man),
(α
βglucose (β-Glc), 6-sulfo-ββ-D-glucosamine (6-sulfo-β-D-GlcNAc)
GlcNAc) and sialic acid were
attached to a substrate through click chemistry. It was determined that Aβ42
Aβ had the
strongest binding affinity towards 66-sulfo-β-D-GlcNAc followed by sialic acid, β-Gal, βGlc, β-GlcNAc, and α-Man.
Man.
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Synthesis of soluble glycomonomers and glycopolymers has been documented in
the literature, though not for Aβ aggregation research. We previously reported the
attachment of D-glucuronic acid sodium salt to aminopropyl methacrylamide for
polymerization via aRAFT.14 The addition was successful; however, this, like many
other glyco-systems,15 utilized chemistries that remove a portion of the biological
relevance, as the attachment of D-glucuronic acid sodium salt resulted in glycomonomer
pendant to the polymer backbone through a nitrogen rather than an oxygen, and
stereochemical control at C1’ was not obtained. McCormick et al. reported kinetic data
for the homopolymerization and chain extension of a methacrylate glycan monomer via
aRAFT, using a dithioester chain transfer agent (CTA).15b Ambrosi et al. reported the
synthesis and the free radical polymerization of glucose and galactose functionalized
methacrylates with retention of β stereochemistry at C1’.16 Parry et al. synthesized a
methacrylamide glycan monomer that maintained α stereochemistry at C1’ and was
polymerized via RAFT in a DMF:H2O mixture using a dithioester as the chain transfer
agent.17
To our knowledge, the synthesis of acrylamide based glycomonomers with
controlled stereochemistry at the C1’ carbon and their polymerization via aRAFT have
not been previously reported. Additionally, the effects of glucose and galactose on the
aggregation of Aβ have not been clearly established. Previous studies, using simple
sugars and sugar microarrays, show contradictory results,12-13 and appropriate biorelevant
concerns are not considered, such as (1) stereochemistry of the sugar to monomer
attachment, and (2) concentration and localization of the representative saccharides.
Finally, investigation of the aggregation processes of Aβ species formed in the presence
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of soluble glycopolymers has not yet been reported. In this paper, synthesis of galactose
and glucose glycomonomers with an acrylamide backbone, is detailed, as well as the
RAFT controlled homo- and co-polymerization of N-dimethyacrylamide, 2- (β-Dgalactosyloxy)ethyl acrylamide (GalEAm) and β-glucosyloxy)ethyl acrylamide
(GlcEAm). Aβ aggregation testing in the presence of glycopolymers, done through ThT
fluorescence and SDS-PAGE is also described.

10
CHAPTER III
EXPERIMETAL DETAIL FOR GLYCOPOLYMER ARCHITECTURES
Research Overview
From previously reported results, it is clear that gangliosides present in the lipid
bilayer of eukaryotic cells, when in sufficient concentrations, provoke aggregation of Aβ
peptides. Sialic acids as well as a ceramide tail are present in all gangliosides, leaving
differences in saccharide moieties and distribution as the only differentiable
characteristics between gangliosides. Unfortunately, control over sugar chemistry in
biomacromolecules is very difficult, with the isolation of a specific saccharide and
saccharide distribution being nearly impossible utilizing traditional biochemical
techniques. To alleviate these difficulties, this project aimed to generate synthetic
polymer models with glucose and galactose, as pendant groups, through the use of
aRAFT controlled radical polymerization to develop a fundamental understanding of how
Aβ peptides interact with saccharides on GM1 gangliosides. aRAFT polymerization will
be employed to achieve the specificity needed to properly evaluate the effects of
saccharides. The results from these studies will help to resolve the previously reported
contradictory findings for Aβ peptide-saccharide aggregation. In this chapter the
synthesis of galactose and glucose glycomonomers with an acrylamide backbone, is
detailed, as well as the RAFT controlled homo- and copolymerization of N-dimethyl
acrylamide, 2- (β-D-galactosyloxy)ethyl acrylamide (GalEAm) and β-glucosyloxy)ethyl
acrylamide (GlcEAm). Aβ aggregation testing in the presence of glycopolymers, done
through ThT fluorescence, and SDS-PAGE and immunoblotting, is also described.
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Objectives of Research and Research Questions
This project aimed to develop a synthetic polymer platform that mimics the
saccharide head groups of gangliosides for investigation into Aβ peptide aggregation and
future saccharide related environmental questions. The goal of this project was achieved
through several research objectives and questions:
I.

Glycomonomers synthesized with correct stereochemistry at the C1’ carbon of
either glucose or galactose.
a. Can sufficient yield be obtained for the addition of HEAm to
dehalogenated saccharide despite the inherent tendency for HEAm to
retain water, which when present generates a competitive reaction?

II.

Glycomonomers polymerized into homo- and statistical copolymers, with N,
N-dimethyl acrylamide via aqueous RAFT.
a. Does the steric properties of the bulky saccharide affect the ability of
RAFT to control the molecular weight and PDI when higher MW
glycopolymers are targeted?
b. Will copolymerization of the glycomonomers with DMA result in a
statistical distribution of each monomer?

III.

Aβ peptides aggregation monitored in response to each (glyco)polymer and
compared to Aβ peptides aggregation in environments free of (glyco)polymers
and other aggregation affecting agents.
a. Do our considerations for biorelevance result in a clear answer for the
environmental effect of saccharides on Aβ peptides, resolving conflict in
previous research?
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b. Does the stereochemistry of the C4’ carbon, which separates glucose and
galactose, provide enough of a change in environment to alter the
aggregation of Aβ peptides?
Materials and Methods
Materials
For protected glycomonomer synthesis, acetobromo-α-galactose, ≥95% (AcGal)
(Sigma-Aldrich, USA), acetobromo-α-glucose, ≥95% (AcGlc) (Sigma-Aldrich, USA),
silver trifluoromethanesulfonate, >99% (silver triflate) (Sigma-Aldrich, USA), sodium
sulfate, >99% anhydrous (Sigma-Aldrich, USA), and powdered 3Å molecular sieves
(Sigma-Aldrich, USA) were used as purchased. N-Hydroxyethyl acrylamide (HEAm)
(Sigma-Aldrich, USA) was filtered through neutral aluminum oxide (Sigma-Aldrich,
USA) to remove the inhibitor. Dichloromethane (DCM) (Sigma-Aldrich, USA) was
distilled from calcium carbonate under nitrogen gas. For glycomonomer deprotection,
sodium methoxide, 30 wt% in methanol (Sigma-Aldrich, USA), methanol, 98.8%
anhydrous (MeOH) (Sigma-Aldrich, USA), and Dowex® 50WX2 (Sigma-Aldrich, USA)
were used as purchased. Polymerization utilized sodium acetate, >99% anhydrous
(Sigma-Aldrich, USA), and acetic acid, glacial (Fisher Scientific) for a 0.11M buffer
(0.025 M acetic acid, 0.075 M sodium acetate). N,N-Dimethylacrylamide (DMA)
(Sigma-Aldrich, USA) was distilled, under vacuum, to remove the inhibitor.
Additionally, 4,4’-Azobis(4-cyanovaleric acid), ≥98% (V-501) (Sigma-Aldrich, USA)
was used as the initiator. 4-cyano-4-(ethylsulfanylthiocarbonylsulfanyl)pentanoic acid
(CEP) was used as the chain transfer agent (CTA) and was synthesized via previously
published procedures.18 For testing with Aβ peptides, Aβ 42 was synthesized by and
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purchased from the Peptide Synthesis Facility at the Mayo Clinic (Rochester, MN) using
routine Fmoc (N-(9-fluorenyl) methoxycarbonyl) chemistry. MALDI-TOF mass
spectrometry revealed >90% purity of the peptide. Sodium dodecylsulfate (SDS) and
thioflavin-T (ThT) were procured from Sigma-Aldrich (USA). All other chemicals were
obtained from VWR Inc.
Synthesis of 2-(2’,3’,4’,6’-Tetra-O-acetyl-β-D-galactosyloxy)ethyl acrylamide
(AcGalEAm) and 2-(2’,3’,4’,6’-Tetra-O-acetyl-β-D-glucosyloxy)ethyl acrylamide
(AcGlcEAm).
Elimination of water was paramount for the successful synthesis of AcGalEAm
and AcGlcEAm; therefore, all glassware was heated in an oven at 140°C for 30 minutes
and cooled under nitrogen. AcGal or AcGlc (26 g, 65 mmol) was added to a solution of
HEAm (5 eq.) and 5% powdered molecular sieves in DCM (1000 mL), while stirring
under nitrogen for one hour. Silver triflate (1.5 eq.) was then added, maintaining a
positive pressure of nitrogen, and then the mixture was allowed to stir for 24 hours
(Scheme 1). After addition of silver triflate, the positive pressure of nitrogen was
removed and the reaction mixture was kept under closed conditions, maintaining an air
free environment. The appearance of a gray/purple sediment indicated the progress of the
reaction, as silver bromide, a light sensitive byproduct, precipitated. The final solution
was filtered, washed with 1M HCl (3x), to remove excess HEAm, and dried over sodium
sulfate. Rotary evaporation and lyophilization resulted in a faintly peach colored solid
(Yield: ~70%). AcGalEAm, 1H NMR (300 MHz, DMSO): δ [ppm] 2.00, 2.06, 2.16 (d,
m, m; 12H-m, n, o, p); 3.52 (m; 2H-e); 3.60, 3.75 (m, m; 1H-d, 1H-d); 3.92 (m; 1H-l);
4.14 (m; 1H-k); 4.48 (m; 1H-k); 5.02 (d of d; 1H-j); 5.20 (m, 1H-g); 5.40 (t; 1H-h); 5.67
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(d of d; 1H-a); 6.10 (m; 1H-b); 6.31 (m; 1H-C). AcGlcEAm, 1H NMR (300 MHz,
DMSO): δ [ppm] 2.06 (m, 12H-m, n, o, p); 3.56 (m, 2H-e); 3.73, 3.89 (m, m; 1H-d, 1Hd); 4.14 (m, 1H-l); 4.24 (m; 1H-k); 4.52 (m; 1H-f); 4.99 (m; 1H-j); 5.10 (m, 1H-g); 5.22
(m; 1H-h); 5.66 (d of d; 1H-a); 6.13 (m; 1H-b); 6.30 (m, 1H-c).

Scheme 1. Synthesis of AcGalEAm. The same conditions were employed to prepare
AcGlcEAm.
2- (β-D-galactosyloxy)ethyl acrylamide (GalEAm) 2- (β-D-glucosyloxy)ethyl acrylamide
(GlcEAm).
AcGalEAm and AcGlcEAm were deacetylated by an established procedure.16
Sodium methoxide (1 mL per 10 mL of solvent) was added to a solution of either
AcGAlEAm or AcGlcEAm in methanol, while it stirred under nitrogen, and the mixture
was allowed to react for 40 minutes (Scheme 2). Dowex® 50WX2 was then added to the
reaction mixture to absorb sodium cations and neutralize the solution and allowed to stir
for 15 minutes. A faintly peach colored, hygroscopic solid was obtained after filtration,
rotary evaporation and lyophilization. GalEAm, 1H NMR (300 MHz, D2O): δ [ppm] 3.2-
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d’, e’, f’, g’, h’, i', h’, k’, l’); 4.20 (d, 1H
1H-f’);; 5.56 (d of d; 1H-a’);
1H
6.03 (m;
3.8 (m; 10H-d’,
1H-c’, 1H-b’). GlcEAm, 1H NMR (300 MHz, D2O): δ [ppm] 3.0-3.85
3.85 (m; 10H-d’,
10H
e’, f’,
g’, h’, i', h’, k’, l’); 4.27, 5.02 (d of d, d of d; (1H
(1H-f’); 5.57 (d of d; 1H-a’);
a’); 6.04
6.0 (m; 1Hc’, 1H-d’).

Scheme 2. Deacetylation of AcGalEAm to form the desired monomer, GalEAm. The
same conditions were utilized to form GlcEAm.
Aqueous RAFT Polymerization of Glycopolymers.
Utilizing aqueous RAFT polymerization, polymer molecular weights were
targeted by selecting appropriate initial monomer and CTA concentrations. The ratio of
M0:CTA0 was set to be approximately 500:1 and 100:1,, with an expected conversion of
60% and 30%, too yield a degree of polymerization of ~
~300 and 30,, respectively.
respectively The
monomer concentration of the reaction was 0.5 M. V-501 was used as the initiator. For
polymerizations targeting a DP of 300
300, CEP was used as the chain transfer agent (CTA)
at a ratio of CTA0:I0 of 5. For polymerizations targeting a DP of 30, CEP was used at a
ratio of CTA0:I0 of 10. The polymerization took plac
place in 0.1
1 M sodium acetate buffer
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(pH 5), with benzene sulfonic acid as an internal standard (25 mg), at 70°C.19 Methanol
was added in low quantities (200 µL) to improve the solubility of CEP in the aqueous
media (Scheme 3). After the completion of the reaction, the solutions were quenched in
liquid nitrogen and exposed to air. Each solution was then dialyzed against water for 72
hours, lyophilized for 72 hours and then stored in desiccant until testing. For the purpose
of this paper, polymers are referred to as either PGal or PGlc to identify homopolymers
of GalEAm or GlcEAm, respectively. The subscript number, as in PGal300, indicates the
targeted degree of polymerization.

Scheme 3. Representative aqueous RAFT polymerization of GalEAm. Identical
conditions were used for all homo- and copolymerizations. The CTA, on top of the
reaction arrow, is CEP and the initiator, below the reaction arrow, is V-501.
Nuclear Magnetic Resonance (NMR)
1

H NMR was performed with a Varian MercuryPLUS 300 MHz spectrometer in

CDCl3, utilizing delay times of 2 s to confirm monomer synthesis and identify the
structures of PGal, and PGlc homopolymers, and the PDMA-stat-PGal/PDMA-statPGlc
copolymers. 64 scans were taken for each experiment with a 3.1 second recycle delay.
For each of the homopolymers, unique peak assignments were made, and the copolymer
compositions were calculated for the statistical polymer via peak integration. 1HNMR
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was also performed on aliquots taken at intervals from reaction mixtures to monitor
conversion and ensure linearity of monomer conversion with time. Conversion was
determined through comparative integration of the internal standard, benzene sulfonic
acid, and the vinylic peaks.
Mass Spectrometry
In order to determine the molecular weight of synthesized AcGalEAm (m/z: 445
+ 23 (Na)), AcGlcEAm (m/z: 445 + 23 (Na)), GalEAm (m/z: 277 + 23 (Na)) and
GlcEAm (m/z: 277 + 23 (Na)), mass spectroscopy was done on a ThermoFinnigan (San
Jose, CA) TSQ 7000 triple-quadrapole instrument that was equipped with an electrospray
ionization source (ESI). The capillary temperature was maintained at a temperature of
200°C, with a voltage of 20 V. The electrospray needle voltage was 4.7 kV, and the tube
lens was maintained between 70 and 100 V. Samples were injected into the ESI source
as a methanol/water (1:1) solution that had sodium chloride to charge the polymers. The
solutions were injected at a rate of 10 µL/sec. All data was analyzed using Xcalibur
(Fischer-Scientific, Inc.) software.
Matrix-Assisted Laser Desorption Ionization (MALDI) Time of Flight Spectrometry
MALDI-ToF was used to determine the molecular weight and polydispersity of
all synthesized glycopolymers. All MALDI was done on a Bruker Microflex, equipped
with a 337 nm nitrogen laser in linear mode and 20 kV accelerating voltage. The detector
gain was set at 5.0x. Pulsed ion extraction (800 ns and 360 ns for higher and lower MW
polymers, respectively) was used during the collection of all data. An average of 100
laser shots was obtained for each polymer. Two poly(styrene) standards, 4,000 g/mol and
50,000 g/mol, were used as external calibration standards. Plates were spotted using a
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thin layer by layer deposition technique. 2,5-Dihydroxybenzoic acid (Sigma-Aldrich,
USA), used as the matrix, was dissolve in HPLC grade THF (50 mg/mL) and then
spotted onto the MALDI plate. Prompt evaporation of THF, via blowing, was used to
obtain small crystals. Each glycopolymer was then dissolved in HPLC grade water (1
mg/mL) and spotted on top of the dried DHB matrices. A heat gun was used to promote
rapid evaporation of water and create smaller glycopolymer crystals.
Amyloid-β Peptide Isolation
Lyophilized stocks of synthetic Aβ 42 were stored at -20 °C desiccated. Briefly,
1.5–2 mg of peptide was dissolved in 0.5 ml of 30 mM NaOH and stored for 15 min at
room temperature prior to size exclusion chromatography (SEC) onto a 1X30-cm
Superdex-75 HR 10/30 column (GE Healthcare) attached to an ÄKTA FPLC system (GE
Healthcare) to remove any preformed aggregates, as reported previously.20 The column
was pre-equilibrated in 20 mM Tris-HCl (pH 8.0) at 25 °C and run at a flow rate of 0.5
ml/min. One-minute fractions were collected. Concentrations of Aβ were determined by
UV-visible spectrometry on a Cary 50 spectrophotometer (Varian Inc.) using a molar
extinction coefficient of 1450 cm-1 M-1 at 276 nm (ExPASy) corresponding to the single
tyrosine residue in Aβ 42. Peptide integrity after SEC was again confirmed by MALDIToF mass spectrometry, which showed a monoisotopic molecular mass of 4516.31 Da, in
good agreement with a calculated mass of 4513.13 Da. Monomeric Aβ 42 fractions were
stored at 4°C and used within 2–5 days of SEC purification in all experiments to avoid
any preformed aggregates in our reactions.
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Thioflavin Fluorescence Spectroscopy (ThT Fluorescence)
ThT fluorescence assays were performed as previously reported.5 Briefly, 5 µL
aliquots of reactions were diluted with 70 mL of 10 µM ThT in 20 mM Tris, pH 8.0 in a
quartz microcuvette. ThT fluorescence was performed by exciting at 450 nm and
monitoring the emission at 482 nm in kinetic mode for 1 min with excitation and
emission slits were set at 10 nm.
Polyacrylamide Gel Electrophoresis (PAGE)
Samples were dissolved in loading buffer (1X Laemmli buffer) containing 1%
sodium dodecyl sulfate (SDS), applied without heating to 4–20% Mini-PROTEAN TGX
gels (Biorad) containing bis-Tris, and resolved in Laemmli running buffer with 0.1%
SDS. Dye-linked molecular mass markers (Blue Plus2 Prestained Standards, Invitrogen)
were run in parallel for calibration. Gels were visualized using a silver stain kit (Pierce)
following standard protocols provided from the manufacture.
Results and Discussion
Monomer and Polymer Synthesis
AcGlcEAm and AcGalEAm glycomonomers were synthesized using a
modification of the procedure reported by Ambrosi et al.16 as described in the
experimental section and illustrated in Scheme 1. We chose to synthesize acrylamidebased glycomonomers, rather than the methacrylate monomers studied by Ambrosi et al.,
to take advantage of their ready polymerization in aqueous solution under moderate
reaction conditions, hydrolytic stability, solubility over a range of pH and salt
concentrations, and relatively simpler purification. In our system, silver triflate was
substituted for silver carbonate in the traditional Koenigs-Knorr reaction. The reactions
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were performed at room temperature over a period of 24 hours and excess HEAm was
removed through acid washes, leaving the saccharide functionalized acrylamide,
AcGalEAm and AcGlcEAm, in the organic layer (1H NMR in Figures 3 and 4, yield
70%). In the Ambrosi methacrylate system, on the other hand, -40°C
40°C reaction conditions,
increased reaction time of 48 hrs, and product purification by column chromatography
were required. They polymerized protected and deprotected monomer and concluded
conc
that deprotection of the monomer prior to polymerization resulted in better removal of the
acetyl groups. Due to the increased hydrolytic stability of the amide linkage in our
acrylamide system, concern over the decomposition of the monomer during deprotection
d
was eliminated. Sodium methoxide in methanol was used to remove the acetyl protecting
groups,, and complete deacetylation occurred without loss of product ((Figures
Figures 5 and 6).
To our knowledge, this is the first report of the synthesis of an acr
acrylamide
ylamide glycomonomer
with a specific attachment at the C1’ carbon of either glucose or galactose.

Figure 3. 1H NMR, in deuterated chloroform, of AcGalEAm, with proton peaks assigned.
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Figure 4. 1H NMR, in deuterated chloroform, of AcGlcEAm, with proton peaks assigned.

Figure 5. 1H NMR, in deuterated water, of GalEAm after de
de-protection
protection with proton peaks
assigned.

Figure 6. 1H NMR, in deuterated water, of GlcEAm after de
de-protection
protection with proton peaks
assigned.
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Confirmation of the stereochemistry at the C1’ carbon was achieved through 1H
NMR analysis. Bubb et al. identified the proton peaks correlating to the α and β
enantiomers for glucose modified at the C1’ carbon.21 With this knowledge and a
1

HNMR of enantiomeric D-glucose and D-galactose, identification of the proton peaks

correlating with the α- and β-enantiomers of synthesized monomers was easily
determined. Figure 7 shows 1HNMR spectra of D-galactose (upper) and GalEAm
(lower), where the peak for the α-enantiomer for galactose appears around 5.0 ppm and
the β-enantiomer proton peak is located around 4.20 ppm. Figure 8 shows a similar
comparative spectrum for D-glucose and GlcEAm. Integration of the α and β proton
peaks for GalEAm (Figure 7) and GlcEAm (Figure 8), showed that 98% and 88%,
respectively, of the monomers had the desired β orientation at C1’. It is possible that the
GlcEAm showed less stereochemical control than the GalEAm because of neighboring
group effects in glucose, which has the C4’ hydroxyl group equatorially positioned and
may sterically affect the β-enantiomer.
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D
Figure 7. Representative 1H NMR showing C1’ stereochemistry of stock D-galactose
(upper) as compared to synthesized GalEAm (lo
(lower),
wer), where GalEAm has 98% of the
desired β-linkage.
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Figure 8. Representative 1H NMR showing C1’ stereochemistry of stock D-glucose
D
(upper) as compared to synthesized GlcEAm (lower), where GlcEAm has 88% of the
desired β-linkage.
Four homopolymers of GalEAm and GlcEAm at differing molecular weights and
copolymers of DMA with GalEAm and GlcEAm were synthesized via aRAFT
polymerization, following the reaction procedure outlined in Scheme 3. In Table 1 is a
summary of the theoretical MWs. Figures 9, 10, 11 and 12 are representative 1H NMR
spectra of PGal300, PGlc300, PDMAGal300 and PDMAGlc300, respectively. The vinyl peaks
of the monomers are no longer present and are replaced by methylene peaks of the
polymer backbones at 1.0 - 2.0 ppm, indicating successful polymerizations. Furthermore,
unique peaks of d’, e’ (2.8 ppm) for DMA and d, e, g, h, i, j, k, l (3.0-3.9
3.9 ppm) for both
GalEAm and GlcEAm (Figures
Figures 11 and 12,, respectively) were identified and integrated to
determine the mol% of monomers in each copolymer. As indicated in Table 1,
1
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incorporation for all monomers was close to the theoretical prediction, with GalEAm and
GlcEAm representing 37% and 32% of their respective copolymers.
Table 1
Summary of aRAFT polymerized glycopolymers
Polymer
1. PGal300
2. PGal30
3. PGlc300
4. PGlc30
5. PDMAGal300
6. PDMAGlc300
a

Mnth(g/mol)

a

88,000
8,500
79,000
7,500
50,700
110,200

mol% Sugarexp
100
100
100
100
37b
3

Theoretical calculations based upon [Mo]/[CTA]. bTheoretically, 56 mol% DMA and 44 mol% GalEAm. cTheoretically, 61 mol%

DMA and 39 mol% GlcEAm.

Figure 9. Representative 1H NMR, in deuterated water, of PGal300.
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Figure 10. Representative 1H NMR, in deuterated water, of PGlc300.

Figure 11. 1H NMR, in deuterated water, of PDMAGal300.

Figure 12. 1H NMR, in deuterated water, of PDMAGlc300.
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The controlled nature of the polymerization of the homopolymers and copolymers
was confirmed through the linear, pseudo first order increase of ln(Mo/M) as a function
of time (Figure 13), where Mo is the initial concentration of monomer and M is the
monomer concentration at any given time point. An initialization period was seen for all
polymers (90 minutes for PGal30 and PGlc30, 30 minutes for PGal300 and PGlc300, and
15 minutes for PDMAGal300 and PDMAGlc300). Researchers attribute this
initialization period to the time in which it takes for every CTA molecule to relinquish its
R group and add a monomer unit. This is not uncommon with less stable acrylamide
radicals, as the CTA prefers to continue interacting with its more stable R group.22 As a
result, a shorter inhibition period is observed for higher monomer to CTA ratios, as there
are fewer CTAs that must add monomer. DMA, appears to be a more stable radical than
GalEAm and GlcEAm, adds more quickly to the CTA, resulting in a shorter initialization
period for the copolymers.
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Figure 13. Kinetic plot of ln([M0]/[M]) as a function of time for a) PGal300, PGlc300, b)
PGal30, PGlc30 and c) PDMAGal300, PDMAGlc300. The linear relationship indicated that
the polymerization followed a predictable controlled behavior.
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Additionally, the rate of polymerization varied between the high and low MW
homopolymers, the copolymers and the type of sugar monomer present in each polymer,
as seen in Figure 13a-c. Across all MWs and polymer compositions, the rate of reaction
was faster for polymers with GalEAm, as opposed to GlcEAm. It is currently not
understood why monomers that differ at only one stereocenter (C4’) would display
different reaction rates. The rate of reaction was also faster for the lower molecular
weight polymers (PGal30 and PGlc30), as compared to the higher molecular weight
polymers (PGal300 and PGlc300). This is attributed to the greater number of radicals
present in the lower molecular weight systems.23 Statistical copolymerization of DMA
with GalEAm and GlcEAm resulted in an increase in the rate of polymerization as
compared to both MWs of sugar homopolymers.
Evaluation of Aβ aggregation in the presence of glycopolymers
Aβ aggregation was evaluated by ThT fluorescence and SDS-PAGE. In Figure
14, ThT fluorescence emission spectra as a function of incubation time for Aβ monomer
incubated alone (control) and with DP 300 and DP 30 galactose and glucose
glycopolymers, respectively, is shown. An increase in intensity indicates the presence of
hydrophobic association of ThT with the molecules. For the Aβ control sample, a
characteristic sigmoidal curve is exhibited, which is associated with formation of
oligomers that associate to eventually form fibrillar structures. The lag time, or the time
before increase in fluorescence associated with aggregation is observed, was shorter for
DP 300 PGal than for the Aβ control, showing increased ThT fluorescence at 24 hrs.
PGal and PGlc, with DP 30, and PGlc300 increase the lag time of aggregation to 72 hours.
For the high molecular weight PGal300 and PGlc300 glycopolymers, fluorescence intensity
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plateaus at around 3 a.u. and 1.5 a.u. after 24 and 72hrs, respectively, suggesting that a
stabilized aggregate species is formed. Notably, the PGlc300 sample dramatically
increases the lag time, indicating a uniquely different association pathway for this system.
ThT fluorescence for the PGal30 solutions does not appear to be statistically different
from that of the control, while that of PGlc30 solutions
ons is dramatically slower and does
not reach the level of the control solution until the final testing point at 144 hours. This
indicates that the presence of glucose glycopolymers alters the aggregation pathway. At
the final testing point of 144 hours, the low molecular weight glycopolymer solutions and
the control show similar levels of fluorescence, indicating the presence of highly
aggregated species. The high molecular weight glycopolymer solutions, however, show
constant low fluorescence levels in
indicative
dicative of a different type of aggregation.

Figure 14. ThT fluorescence emission intensity as a function of time for PGal300, PGal30,
PGlc300, and PGlc30 with A
Aβ 42, at a ratio of 1:3 (Aβ:polymer).
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SDS-PAGE analysis was performed at 72 and 144 hours of incubation (Figure
15). The lane furthest to the left, labelled monomer control, shows a single band at
around 3.5 kDA after 72 hours and no band after 144 hours, indicating that in the absence
of glycopolymer the Aβ exists in the monomer or highly aggregated state (MW too large
to enter the gel). The PGal30 and PGlc30 lanes show bands at 3.5 kDA and light stains
around 200 kDA at 72 hours of incubation, indicating that the Aβ in these solutions exist
as monomers or high MW oligomers. At 144 hours of incubation, the monomer band is
lighter and the 200 kDA oligomer band is more clearly seen. The Aβ solutions incubated
with PGal300, at both time points, show bands at 3.5 and 13 kDA, and a diffuse, heavy
band at 50-200 kDA, indicating the presence of monomer, low molecular weight
oligomers, and high molecular weight oligomers of 11-44mer Aβ units that do not
proceed to form fibrils within the tested period. Aβ solutions incubated with PGlc300,
however, show heavier bands at 13-18 kDA, which correlate to 3-4mer Aβ units, as well
heavy diffuse bands corresponding 11-44mers from 50 – 200 kDA. For the PGlc300 the
monomeric Aβ is not present at 72hrs, in contrast to the other environments tested,
indicating that PGlc300 quickly causes the formation of oligomers. This is significant as
the smaller 3-4mer Aβ units are thought to be the most toxic form of Aβ.5, 20
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PAGE of A
Aβ aggregates that resulted from incubation with glucose and
Figure 15. SDS-PAGE
galactose glycopolymers of DP 30 and 300. Glycopolymers are not affected by silver
stain and do not appear on the gels.
These results confirm that galactose
galactose- and glucose-containing
containing glycopolymers
directly influence the aggregation of A
Aβ,, and provide an indication of the expected
effects of gangliosides on A
Aβ aggregation. Both systems promote the formation of large
oligomeric aggregates that
hat resemble proto
proto-fibrils,
fibrils, while glucose also promotes the
formation of smaller toxic oligomers.
Chapter Summary
Glucose and galactose glycomonomers, with an acrylamide backbone, were
synthesized, maintaining control over the stereochemistry at the C1’ ca
carbon.
rbon. They were
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polymerized with DMA via aqueous RAFT to produce homopolymers and copolymers of
precise molecular weights. Interestingly, different reaction kinetics were observed for the
two sugar monomers, GalEAm and GlcEAm, as well as for the various homopolymers
and copolymers. Specifically, GalEAm reacts much faster than GlcEAm and the lower
MW polymers react faster than the higher MW polymers. Aggregation kinetics and
aggregate size of Aβ in the presence of high and low MW glycopolymers were evaluated.
Aβ incubated with the PGal300 and PGlc300 remained at aggregation sizes attributable to
oligomers, with PGlc300 promoting smaller oligomers (3-4mer) that are potentially more
toxic. PGal300 also reduced the time required for initial aggregation (lag time). Glucose
and galactose glycopolymers with DP 30 increased the lag time of aggregation but
ultimately do not impede fibril formation. We report a new platform for synthesis of
glycopolymers of controlled architecture which can accommodate a range of biologically
relevant saccharides for evaluation of Aβ aggregation pathways in the presence of
polysaccharide interfaces.
Recommendation for Future Work
Isolation of oligomeric species, resulting from incubation of Aβ monomer with
PGlc300, would be an important next step in this project. This would allow for
determination of the stability of the oligomeric species, identifying if the aggregation
process is “on” or “off” pathway, as described by Kumar et al.20 Additionally, it would
allow for conformational analysis of each oligomeric species through circular dichroism
(CD). It is currently assumed that the aggregates have formed β-sheets; however, CD
must be done to confirm.
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The control provided by RAFT polymerization of acrylamide based
glycopolymers could also allow for the investigation of other saccharides, such as Nacetyl-D-galactosamine, that are present in GM1 gangliosides, as an incomplete
understanding of the GM1 ganglioside head group has been obtained. An alternative
monomer synthesis would need to be utilized. Namely, β-alanine would be reacted with
acyl chloride, under anhydrous conditions, in order to synthesize an acrylamide monomer
with a pendant carboxylic acid. Subsequently, N-acetyl-D-galactosamine, using N,N'dicyclohexylcarbodiimide coupling, could be added to the pendant carboxylic acid.
aRAFT polymerization, using the previously described conditions, could then be done to
obtain multiple MWs of the galactosamine monomer, which would then allow for a
comparative study of Aβ aggregation.
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CHAPTER IV
ANTIMICROBIAL PEPTIDE MIMICS AND BACTERIAL INTERFACE
Chapter Overview
This chapter aims to inform the reader of pertinent literature pertaining to
antimicrobial peptides and antimicrobial peptide mimics, providing the argument and
need for the research presented in Chapter V. Specifically, naturally occurring
antimicrobial peptides (AMPs) display the ability to eliminate a wide variety of bacteria,
without toxicity to the host eukaryotic cells. Synthetic polymers containing moieties
mimicking lysine and arginine components found in AMPs have been reported to show
effectiveness against specific bacteria, with the mechanism of activity purported to
depend on the nature of the amino acid mimic. In an attempt to incorporate the
antimicrobial activity of multiple amino acids in a single water soluble copolymer, a
series of copolymers containing lysine mimicking aminopropyl methacrylamide (APMA)
and arginine mimicking guanadinopropyl methacrylamide (GPMA) were prepared via
aqueous RAFT polymerization. Copolymers were prepared with varying ratios of the
comonomers, with degree of polymerization of 30 and narrow molecular weight
distribution to simulate naturally occurring AMPs. Antimicrobial activity against Gram
negative and Gram positive bacteria, and selectivity via hemolysis of red blood cells and
MTT assays of MCF-7 cells, were determined. It was found that broad spectrum
antimicrobial effectiveness, including Pseudomonas aeruginosa, was obtained for
polymers with high levels of APMA, with low toxicity toward eukaryotic cells.
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Important Literature
Antimicrobial peptides (AMPs) are naturally occurring defensive agents that
eliminate a wide range of bacteria and are found in a variety of eukaryotic organisms,
including mammals, insects, and plants. Over 500 unique AMPs are catalogued.24
Researchers believe that specific environmental needs influence the composition of
AMPs. However, these peptides display several consistent characteristics, including a
composition of 20-50 amino acid residues, distinct hydrophobic and hydrophilic regions,
and a net positive charge at physiological pH (7.4). The hydrophilic regions have an
abundance of lysine and arginine amino acid residues, which are protonated and
positively charged under physiological conditions. It is this net positive charge that
enables AMPs to selectively bind to bacteria, as their membranes are negatively charged,
and induce cell death. The host eukaryotic cells have a net neutral charge and, therefore,
do not have as high an affinity for AMPs, resulting in an efficient and selective defense
against bacteria.
AMPS are of interest because bacteria do not appear to develop resistance to
AMP activity as readily as they do against current synthetic antibiotics. Unfortunately,
isolation or synthesis of sufficient quantities of AMPs is difficult and costly. Polymeric
mimics of AMPs are a desirable alternative because they have the potential to be
produced at reduced cost and are easier to synthesize.25
Several parameters are known to affect the efficacy of successful AMP mimics.
First, polymers of lower molecular weight, around that of natural AMPs, show greater
antimicrobial activity than monomers or higher molecular weight systems.26 Second, the
amphipathic balance of the polymer mimic is essential for optimal antibacterial activity
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as well as selectivity. Polymeric AMPs that are too hydrophobic reduce selectivity and
result in eukaryotic cell death. A number of different methods have been employed to
modify the amphipathic balance in synthetic systems. Researchers increased
hydrophobicity through copolymerization of hydrophobic monomers with alkyl tails of
different lengths with cationic comonomers, which generally resulted in increased
bacterial cell death at the expense of selectivity.27 Multiple polymer backbone structures,
including methacrylates,27a, 27b, 28 β-lactams,29 norbornenes,30 and methacrylamides27c, 31
with varying solubility and inherent polarity have been evaluated as AMP mimics.
Palermo et al. showed that methacrylamide based AMP mimics, due to the increased
polarity of the amide, had a decreased toxic impact on red blood cells as compared to
similar methacrylate based polymers. 27c, 28a These methacrylamide polymers also
demonstrated increased antimicrobial activity, as the more soluble backbone allowed
complete protonation, and, therefore, increased charge density, of the primary amine
cationic moiety.
The choice of cationic moiety also impacts the effectiveness of synthetic AMP
mimics. Mostly primary amines,27b, 29-30, 31 which mimic lysine amino acid residues, have
been employed; however, tertiary31 and quaternary28a amines have also been
investigated. Results indicate, however, that transition from primary to tertiary or
quaternary amines reduces activity and selectivity of AMPs. In our previous work, we
investigated the effect of pendant cation modification with various alkyl groups to alter
the amphipathic ratio of methacrylamide AMPs, and found that unmodified primary
amine cations display superior antimicrobial activity and selectivity.31 Researchers have
also begun to explore guanidinium, which mimics arginine amino acid residues found in
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natural AMPs, as an alternative cationic moiety. Gabriel et al., using a polynorbornene
backbone, reported that substituting guanidinium for primary amines improved selectivity
without affecting the antimicrobial activity.30b Locock et al., using a methacrylate
backbone, reported that guanidinium improved both activity and selectivity.28b
Naturally occurring AMPs demonstrate different mechanisms of bacterial cell
death based on the prevalence of lysine or arginine in the peptide. The two principal
mechanisms are (1) cell penetration, which correlates with a predominance of arginine,
and (2) membrane disruption, which correlates with an increased occurrence of lysine.24,
32

Similarly, guanidinium based AMP mimics appear to kill bacterial cells in a manner

that differs from that of primary amine based AMP mimics. Specifically, guanidinium
functionalized polynorbornenes did not demonstrate the bacterial membrane disruption
behavior observed in primary amine functionalized polynorbornenes, suggesting that cell
death proceeded via an alternate mechanism.33 Locock and coworkers reported that
increasing the molecular weight of their guanidinium AMP mimics resulted in reduced
antimicrobial activity, while the antibacterial effectiveness of primary amine AMP
mimics was less sensitive to changes in molecular weight over the range tested. These
findings suggest the possibility of improving antimicrobial properties by incorporating
both lysine and arginine mimics in synthetic AMPS, which should provide the ability to
kill bacteria through different mechanisms and be effective against a wider selection of
bacteria.
Treat and coworkers investigated the viability of poly(3-guanidinopropyl
methylacrylamide) copolymers as cell penetrating vehicles for potential drug delivery
applications. They found that significant amounts of polymer were taken into the
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eukaryotic KB cell through endocytotic and passive pathways.34 These results indicate
the potential reduction in selectivity for guanidinium-containing AMP mimics, and
suggest the need for further study of the effectiveness of the systems. Investigation into
the effect of counterion type on antimicrobial activity is also needed.35 Previous reports
have separately employed TFA or Cl counterions with gauanidinium moieties; however,
to our knowledge, the effects of counterion structure have not been reported.28b, 30b
Antimicrobial activity of AMP mimics has been tested against both gram-positive
bacteria, which have a cell wall that surrounds an inner plasma membrane, and gramnegative bacteria, which have a thin cell wall that is sandwiched between two plasma
membrane layers. Typically, E. coli, Gram-negative, and B. subtilis, Gram positive, are
used as representative bacteria in antimicrobial activity testing. However, to our
knowledge, the effects of synthetic AMPs on Pseudomonas aeruginosa, which displays
an inordinate ability to resist traditional therapeutics and is the most reported nosocomial
bacterium,36 have not yet been evaluated. Staphylococcus aureus, due to the emergence
of methicillin resistant strains, is also of great concern.
In this study, statistical copolymers of aminopropyl methacrylamide (APMA) and
3-guanadinopropyl methacrylamide (GPMA) of controlled molecular weight and
composition are prepared via aqueous RAFT polymerization for determination of the
effects of lysine- and arginine-mimicking pendant groups in a fully water-soluble AMP
mimic on antimicrobial activity and selectivity. Polymers are prepared with molecular
weights similar to those of naturally occurring AMPS, and the effects of counterion type
are examined. The low molecular weights of the synthesized polymers eliminate the
need for built-in biodegradability, as small molecules are removed from the body via the

40
renal system.37 Under the benign aqueous RAFT reaction conditions, Boc-protection of
the amine-containing monomers is not required.
Antimicrobial behavior against E. coli, S. aureus, and P. aeruginosa, and
selectivity testing via hemolysis of red blood cells and MTT assays of MCF-7 cells are
reported. Broad spectrum antimicrobial effectiveness coupled with low toxicity towards
eukaryotic cells is observed for copolymers with high concentrations of the lysinemimicking APMA monomer.
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CHAPTER V
EXPERIMENTAL DETAIL FOR ANTIMICROBIAL PEPTIDE POLYMER MIMICS
Research Overview
Our ultimate goal is to investigate the effectiveness of guanidiniums moieties
within our established methacrylamide based platform for AMP mimic development and
tailoring via tuning of (co)polymer composition. Attachment of guanidinium has
previously resulted in improved activity and selectivity of AMP mimics.28b, 30b This
research aims to increase antimicrobial activity and selectiveness across a broader
spectrum of bacteria through pairing of increased solubility of a methacrylamide polymer
backbone and guanidinium pendant groups. In this chapter, we describe a novel method
for GPMA synthesis that allows for improved yield, simplified purification and handling.
Additionally, a range of GPMA-stat-APMA copolymers were synthesized for the first
time using aqueous RAFT polymerization, which allows for control over MW, narrow
PDI and benign reaction conditions. Polymerization, due to the benign reaction
conditions, did not require Boc-protection of APMA or GPMA. Antimicrobial behavior
against E. coli, S. aureus, and P. aeruginosa, which to the best knowledge of the author
has never been reported in polymeric AMP papers, was performed, and selectivity testing
via hemolysis of red blood cells and MTT assays of MCF-7 cells was done. As before,
the low molecular weights of synthesized polymers eliminates the need for built in
biodegradability, as small molecules can be removed from the body via the renal
system.37
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Objectives of Research and Research Questions
I.

Synthesize statistical copolymers of APMA and GPMA via aqueous RAFT
polymerization to expand upon our previous polymeric AMP platform and enable
a systematic evaluation of the effect of pendant guanidinium cations.
a. Is APMA and GPMA able to be statistically synthesized via aqueous RAFT
polymerization?

II.

Determine the antimicrobial activity and selectivity of synthetic AMP mimics as a
function of the polymer guanidinium content and counterion identity.
a. Does the addition of guanidinium increase the antimicrobial activity of
synthesized AMPs over a broader range of bacteria?
b. Is there indication of an alternative bacterial death mechanism with the
incorporation of guanidinium?
Materials and Methods

Materials
For GPMA synthesis, N-(3-aminopropyl) methacrylamide hydrochloride, >98%
(APMA·HCl) (Polysciences, Inc.), triethylamine, >99.8% (TEA) (Sigma-Aldrich, USA),
N, N’-di-boc-1H-pyrazole-1-carboxamidine (PCA) (Sigma-Aldrich, USA), acetonitrile,
anhydrous, 98% (Sigma-Aldrich, USA), sodium sulfate (Sigma-Aldrich, USA),
trifluoroacetic acid (TFA) Sigma-Aldrich, USA) and 4M HCl in dioxane (Fischer
Scientific, USA) were used as purchased. For all polymerizations, 4, 4’-Azobis (4cyanopentanoic acid) (V-501) (Sigma-Aldrich, USA), methanol, anhydrous, 99.8%
(Fischer Scientific, USA), sodium acetate, anhydrous (Sigma-Aldrich, USA), acetic acid,
glacial (Fisher Scientific, USA) and Spectra/Por® dialysis membrane, standard RC
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tubing (3,500 kD) (Spectrum Laboratories, Inc., were used as purchased. 4-cyano-4(ethylsulfanylthiocarbonylsulfanyl)pentanoic acid (CEP) was used as the CTA in all
polymerizations and was synthesized via previously published procedures.18 For
antimicrobial susceptibility testing, Escherichia coli (ATCC), Staphylococcus aureus
(ATCC), Pseudomonas aeruginosa (ATCC), Mueller-Hinton broth (MHB) (Fischer
Scientific) and low salt Luria Broth (10 g/L tryptone, 5g/L yeast extract, 0.5 g/L NaCl)
(LB) (Sigma-Aldrich, USA) were used as purchased. Tris (hydroxymethyl)
aminomethane (Tris) (Sigma-Aldrich, USA) and NaCl (Sigma-Aldrich, USA) were used
to make tris-buffered saline (TBS) (10 mM Tris, 150 mM NaCl, pH 7.4). All selectivity
testing was done with Triton-X 100 (Merck, India), Dulbecco’s Modified Eagle Media
(DMEM) (Himedia, India), fetal bovine serum (FBS) (Himedia, India), Trypsin-EDTA
Solution 1X (Himedia, India), antibiotic solution 100X Liquid (AS) (made with penicillin
and streptomycin) (Himedia, India), (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, India) and dimethyl sulfoxide
(DMSO) (Merck, India), and used as received. Preparation of MCF-7 cells (NCCS,
Pune, India) is discussed in the cell viability section of this paper. Isolation of red blood
cells (RBC) (AIIMS hospital, New Delhi, India) is discussed in the hemolysis section of
this paper.
Synthesis of Boc-protected GPMA
APMA·HCl, dissolved in a mixture of DI water (12 mL) and TEA (20 mL, 148
mmol), was stirred at 25°C. PCA (10 g, 32 mmol), dissolved in acetonitrile (108 mL),
was then added drop-wise, over 30 minutes, to the stirring APMA·HCl solution via an
addition funnel (Scheme 4). The reaction progressed for 24 hr. The product was purified
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via filtration, washed three times with DI water (50 mL) and lyophilized overnight (yield:
91%). 1H NMR (300 MHz, CDCl3): δ [ppm] 1.46 and 1.50 (d, H-G); 1.70 (m, H-D);
2.00 (s, H-C); 3.32 (m, H-F); 3.49 (m, H-E); 5.31 (s, H-A); 5.81 (s, H-B); 7.39 (t, H-H);
8.49 (t, H-I); 11.53 (s, H-J).

Scheme 4. Synthesis of Boc-protected GPMA.
Deprotection of Boc-protected GPMA
Deprotection of GPMA proceeded in one of two ways in order to alter the
counterion coordinated to the guanidinium, as the conjugate base of the acid used to
deprotect becomes the counterion. First, Boc-protected GPMA (10.96 g, 28.48 mmol)
was dissolved in CH2Cl2 (90 mL), stirring at 0°C. TFA (87 mL, 1.14 mol) (20 eq. per
boc-protecting group) was then added to the solution drop-wise via an addition funnel
and the reaction was allowed to progress for 16 hours, while gradually warming from 0°C
to 25°C (Scheme 5). The solvents were removed via rotary evaporation and the resulting
clear viscous oil was dissolved in 250 mL DI H2O, frozen in liquid N2, and lyophilized
for 48 hr. The product was obtained as a white solid. Second, Boc-protected GPMA was
dissolved in 4M HCl in dioxane (7 eq. per boc-protecting group) and allowed to react
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overnight. The product, a white solid, precipitated from solution and was purified via
filtration and washing with anhydrous dioxane. 1H NMR (300 MHz, DMSO): δ [ppm]
1.65 (m, H-D’), 1.86 (s, H-C’), 3.13 (m, H-E’, F’); 5.34 (s, H-A’); 5.66 (s, H-B’); 7.27 (s,
broad, H-H’, I’); 7.70 (t, H-J’); 8.00 (t, H-K’).

Scheme 5. Deprotection of Boc-protected GPMA with either TFA or HCl, which alters
the resulting counterion for deprotected GPMA.
Polymerization of Antimicrobial Peptide (AMP) Mimics
Utilizing aqueous RAFT polymerization, polymer molecular weights were
targeted by selecting appropriate initial monomer and CTA concentrations. The ratio of
M0:CTA0 was set to be approximately 30:1 to yield a degree of polymerization of ~30,
which mimics the size of naturally occurring AMPs. 4, 4’-Azobis (4-cyanopentanoic
acid) was used as the initiator. For all polymerizations, CTA0/I0=5. The polymerization
was conducted in aqueous acetate buffer (1.5 M sodium acetate and 0.5 M acetic acid, pH
5) at 70°C19 for 6 hr (Scheme 6). Methanol was added in low quantities (~30%) to
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improve the solubility of CEP in the aqueous media. After the reactions were completed
the solutions were exposed to air and quenched in liquid nitrogen. The solutions were
then dialyzed against water for 72 hours, lyophilized for 72 hours, and then stored in
desiccant until subsequent testing (representative yield: 75%). Some polymer was lost in
dialysis due to excessive swelling of the dialysis tubing as a result of internal osmotic
pressure. This loss can be minimized by making the water slightly acidic during the
dialysis procedure to reduce the extent of swelling.
The mol % of GPMA was varied to produce nine homo- and co-polymers. The
nomenclature PGT represents polyGPMA and the corresponding number indicates the
targeted mole fraction in the (co)polymer. For example, PGT25 represents a copolymer
composed of 25 mol% GPMA·TFA and 75 mol% APMA·Cl. The addition of either ·Cl
or ·TFA indicates which counterion was coordinated with GPMA when it was
polymerized.

Scheme 6. Aqueous RAFT polymerization of poly(APMA-stat-GPMA) with either TFA
or Cl as the counterion for GPMA.
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Nuclear Magnetic Resonance (NMR)
1

H NMR was performed with a Varian MercuryPLUS 300 MHz spectrometer in

CDCl3 and DMSO, utilizing delay times of 5 s to determine monomer purity. A 500
MHz NMR equipped with a standard 5 mm 1H/13C probe and operating at 499.77 MHz
(1H) was used to identify the structures of PAPMA and PGPMA homopolymers and the
structures of the poly(APMA-stat-GPMA) copolymers, with counterions of -TFA and -Cl,
in D2O. 64 scans were taken for each experiment with a 3.1 second recycle delay. For
each of the homopolymers, unique peak assignments were made, and the copolymer
compositions were calculated for the statistical polymers via peak integration of
methylene bridge E and E’ on the APMA and GPMA monomer residues, respectively.
The polymerization reaction progress was monitored, and the controlled nature of
the reaction was ensured for PGT50·TFA through aliquots that were taken every hour
from the reaction vial. 1H NMR was utilized to determine [M] at time (t) by comparing
the vinylic hydrogen peak integrations to the integration of an internal standard (MeOH).
Aqueous Size Exclusion Chromatography
The molecular weight and polydispersity index (PDI) of the polymers were
determined by aqueous size exclusion chromatography (ASEC) coupled with multi-angle
laser light scattering (MALLS). Eprogen CATSEC columns (100, 300 and 1000 Å) were
used in combination with a Wyatt Optilab DSP interferometric refractometer (k = 690
nm) and a Wyatt DAWN DSP MALLS detector (k = 633 nm). 1 wt% acetic acid/ 0.1 M
Na2SO4 (aq) was used as the eluent at a flow rate of 0.25 mL/min. The interferometric
refractometer was utilized off-line to determine dn/dc values for PAPMA and PGPMA at
25 °C in the eluent (1 wt% acetic acid/ 0.1 M Na2SO4 (aq)) in order to assign absolute
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molecular weight values to all homopolymers. For the statistical polymers the dn/dc
values were calculated as the mole-fraction-averaged composites of the measured
homopolymer dn/dc values using the copolymer compositions determined by 1H NMR.
Wyatt ASTRA SEC/LS software was used for molecular weight and PDI calculations.
ASEC-MALLS was also utilized to monitor molecular weight as a function of time. The
refractive index (RI) response vs elution volume, for aliquots taken at each time interval,
was collected.
Antimicrobial Susceptibility Assay
Antimicrobial susceptibility was measured using the broth microdilution method
according to the CLSI guidelines.38 Bacterial strains were incubated in MHB and all
measurements were performed in triplicate. Two-fold serial dilutions of each
antimicrobial peptide mimic solution (1000 µg to 15.6 µg /ml) were prepared in a 96 well
Costar® microtiter plate. The microtiter wells were then inoculated with 5 × 105 colony
forming units per ml of each test strain.39 After overnight incubation at 37°C, wells were
analyzed for bacterial growth by measuring OD580 using a plate reader. MHB without
any peptides was also inoculated with each strain and used as a positive control for
microbial growth. Sterile MHB was used as a negative control and as a blank for
absorbance readings. The lowest concentration (µg/ml) of the peptides that completely
prevented bacterial growth was considered the minimum inhibitory concentration (MIC).
Additionally, antimicrobial susceptibility was tested using a procedure developed
by Paslay et al.31 Namely, bacteria were grown overnight in low salt LB and then diluted
to 0.001 OD600. Polymer solutions, in TBS at concentrations of 70, 150, 230 and 300
µg/mL, respectively, were incubated in a 96 well plate overnight at 37°C, with an equal
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volume of the diluted bacterial suspensions. Subsequently, the optical density of each
well was measured using a UV-Vis plate reader to determine the level of bacterial growth
in comparison to the positive and negative standards.
Hemolysis Assay
Hemolysis testing was done in accordance with the procedure previously
published by Paslay et al.31 Whole blood was received from AIIMS hospital in New
Delhi, India, requiring processing in order to isolate red blood cells (RBC). The whole
blood was centrifuged at 1500 rpm for 10 min, resulting in a RBC plug at the bottom of
the centrifuge tube. Undesired serum was decanted, leaving the RBC plug. RBCs (30 µL)
taken from the plug were suspended in TBS (10 mL) and then centrifuged at 1500 rpm
for 10 min. Suspension in TBS and centrifugation was repeated a total of three times to
adequately rinse RBCs. The final RBC solution consisted of rinsed RBCs suspended in
TBS (10 mL). Simultaneously, stock solutions at concentrations relevant to determined
MICs of all homo- and copolymers were made using TBS.
RBCs and polymers solutions were incubated together in micro-centrifuge tubes
at a 1:1 ratio, with a total volume of 1 mL, at 37°C for 30 min. The micro-centrifuge
tubes were then centrifuged at 1500 rpm for 10 min to separate the intact, healthy RBCs
from the rest of solution. The supernatant, containing hemoglobin released from polymer
lysed RBCs, was transferred to a 96-well plate (100 µL in triplicate) where absorbance at
540 nm was determined in a Biotek PowerWave X S2 UV-VIS plate reader. Percent
hemolysis was determined through normalization of the observed absorbance for
individual polymer wells to that of positive (100% hemolysis) and negative (0%
hemolysis) controls.
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MTT Assay
Further selectivity testing was performed as previously described against MCF-7
cancer cells. Cells were grown to 80% confluence at 37°C in a 5% CO2 incubator, using
tissue culture polystyrene flacon flasks and DMEM media that was supplemented with
10% fetal calf serum and 1% antibiotic serum.31 Trypsin was added to dissociate cells
from the flacon flask; cells were counted in a hemocytometer to determine cell
concentration. Fresh media was then added to the flacon flask so that cells could be
seeded into a 96 well plate (100 µL per well). Seeded cells were incubated for 24 hours
at 37°C in a 5% CO2 incubator. The old media was then removed from each well and
replaced with fresh media (100 µL per well). Polymer solutions (50 µL per well) were
added to appropriate wells in triplicate, resulting in final polymer concentrations of 25,
100, 200, 2000 µg/mL, respectively. TBS (50 µL per well) and 3% Triton-X (50 µL per
well) were added, in triplicate, as the positive and negative controls, respectively. Plates
were incubated for either 6 or 12 hrs at 37°C in a 5% CO2 incubator. Old media was then
removed and replaced with new media (100 µL per well). MTT in TBS (10 mg/mL, 10
µL per well) was added and allowed to incubate for 4 hrs at 37°C in a 5% CO2 incubator.
Old media was removed and DMSO (100 µL per well) was added to dissolve formazan
crystals produced by living MCF-7 cells. Absorbance of each well was read at 570 nm
using a Biotek PowerWave X S2 UV-VIS plate reader. Percent cell viability was
determined by normalizing the measured absorbance in polymer wells with the
absorbance in the positive and negative control wells.
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Results and Discussion
GPMA Synthesis and (Co)polymerization
Guanidinium functionalized synthetic AMP mimics were prepared to compare the
broad-spectrum antimicrobial effectiveness of arginine and lysine analogues when
incorporated as pendant groups into fully water-soluble, hydrolytically stable,
methacrylamide copolymers (Scheme 7). We previously demonstrated high selectivity
and toxicity against E. coli (Gram-negative) and B. subtilis (Gram-positive) for lysinemimicking APMA polymers. These findings combined with literature reports of
antimicrobial effectiveness obtained with incorporation of guanidinium moieties in other
polymeric systems,28b, 30b and the McCormick group’s previous copolymer reports of
GPMA synthesis,34 provided the motivation for the current study. Methacrylamide based
monomers were chosen for their previously demonstrated antimicrobial activity and
selectivity, hydrolytic stability, high degree of water solubility, and pKa values (ensuring
ionization at physiological pH).

52

Scheme 7. APMA (b) and GPMA (d) mimics of lysine (a) and arginine (c) amino acid
residues, respectively.
Increased monomer purity and yield for GPMA were obtained through
modifications of the synthe
synthetic methods reported by Treat et al.34 and Gabriel et al.30b
Specifically, APMA·HCl was deprotonated in situ with TEA, allowing nucleophilic
attack on the PCA,, as shown in Scheme 4. The resulting Boc-GPMA
GPMA precipitated at high
yield (~91%) from solution, with byproducts removed through subsequent filtration and
washing with DI water. This reaction was more facil
facilee than the previous synthesis by
Treat et al.,., who reported deacidification of purchased APMA followed by drop-wise
drop
addition to a stirring solution of 22-ethyl-2-thiopseudourea
thiopseudourea and TEA in acetonitrile.
Additionally, the reaction required column chromatogra
chromatography
phy for purification and resulted
in a 72% yield. In our current procedure, GPMA was deprotected, shown in Scheme 5,
before polymerization through a well-established Boc-deprotection
deprotection protocol30b with either
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TFA or HCl. This allowed production of GPMA monomers at quantitative yield with
counterions of different bulkiness and binding affinities.
Table 2
Molecular weight and composition data for GPMA synthesized (co)polymers.
mol %
GPMA
(theory)

mol %
GPMA
(exp)a

Mn,th
(g/mol)b

Mn,exp
(g/mol)c

PDIc

dn/dcd

1. (PAPMA·Cl)

0

0

5,600

6,500

1.06

0.200

2. (PGT25·TFA)

25

23

6,500

6,900

1.03

0.183

3. (PGT50·TFA)

50

45

7,400

6,100

1.06

0.169

4. (PGT75·TFA)

75

72

8,300

5,800

1.12

0.152

5. (PGT100·TFA)

100

100

9,200

8,100

1.04

0.132

6. (PGT25·Cl)

25

30

6,500

7,000

1.11

0.183

7. (PGT50·Cl)

50

44

7,400

7,400

1.12

0.169

8. (PGT75·Cl)

75

67

8,300

8,100

1.16

0.152

9. (PGT100·Cl)

100

100

9,200

9,200

1.11

0.132

Polymer

a

Determined by 1H NMR. bBased on 90% conversion of [M0]. cDetermined by ASEC-MALLS. dDetermined by a Wyatt Optilab

DSP interferometric refractometer.

GPMA copolymers of controlled molecular weight, narrow molecular weight
distribution, and desired composition were prepared via aqueous RAFT polymerization
as described in the experimental section (Table 2). Measured values of molecular weight
and GPMA incorporation are in good agreement with predicted values. All polymers
show narrow molecular weight distributions, with PDIs smaller than 1.2. A plot of
ln([M0]/[M]) for the polymerization of the 1:1 molar ratio of APMA:GPMA·TFA as a
function of reaction time is linear (Figure 16), indicating pseudo first order kinetics and
control of the polymerization. Furthermore, GPC analysis (Figure 17) shows a steady
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increase in MW and narrowing of MWD as a function of reaction time, suggesting
controlled polymerization.

2.5
ln([M0]/[M])

2
1.5
y = 0.0062x - 0.038
R² = 0.9895

1
0.5
0
-0.5

0

100

200
Time (min)

300

400

Figure 16. Poly(APMA-stat
stat-GPMA) reaction kinetics. Kinetic plot of ln([M0]/[M]) as a
function of time for the polymerization of 1:1 molar ratio of APMA:GPMA·TFA.

4 hr

5 hr
3 hr
2 hr

1 hr

stat-GPMA) molecular weight distribution and conversion as a
Figure 17. Poly(APMA-stat
function of reaction time for the polymerization of 1:1 molar ratio of
APMA:GPMA·TFA.
In a representative 1H NMR spectrum of poly(APMA-stat-GPMA)
GPMA) targeted at a
50:50 mole ratio (Figure
Figure 18
18),, clearly identifiable peaks for the monomer residues of both
APMA and GPMA are visible. The methylene bridge carbon nearest the amide, labelled
D in Figure 18,, is attributed to both APMA and GPMA residues. For proper integration,
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comparison of protons labelled E (2.8 ppm), from APMA, and E’ (3.0 ppm), from
GPMA, and removal of proton contribution from D (3.0) are required. Evaluation
E
of the
integrated peaks
eaks indicates 45 mole % incorporation of GPMA into the copolymer,
copolymer which
is close to the target composition
composition. Similar kinetic plots, GPC traces, and 1H NMR
analyses were obtained for all copolymer compositions. It was important to ensure that
the targeted MW and copolymer composition were achieved in order to separate the
effects of MW and MWD from those of polymer composition and counterion type on
antimicrobial activity and selectivity.

Figure 18. A representative 1H NMR spectrum of poly(APMA-stat-GPMA
GPMA) copolymer
(1:1 molar ratio of APMA:GPMA·TFA in feed).
Antimicrobial activity
Broth microdilution testing
testing,, as described in the experimental section, was
completed to determine the effectiveness of the controlled copolymers as antimicrobial
agents. Activity was quantified based on the minimum inhibitory concentration (MIC),
which is the polymer concentration at which 100% cell death occur
occurs. Results of the broth
microdilution studies are provided in Figure 19 as plots of UV-Vis absorbance as a
function of polymer concentration for each of the copolymer compositions against (a) S.
aureus, (b) E. coli,, and (c) P. aeruginosa.. Lower absorbance indicates higher activity.
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For the copolymers providing 100% cell death in the therapeutic range (concentrations ≤
1000 µg/mL), MIC is tabulated in Table 3.

Absorbance (580 nm)
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1
0.8
0.6
0.4
0.2
0

Absorbance (580 nm)

Concentration (µg/mL)
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

a
PGT100·TFA
PGT100·Cl
PGT75·TFA
PGT75·Cl
PGT50·TFA
PGT25·TFA
PGT50·Cl
PGT25·Cl
PAPMA·Cl

PGT100·Cl b
PGT100·TFA
PGT75·TFA
PGT75·Cl
PGT50·TFA
PGT25·TFA
PGT50·Cl

Absorbance (580 nm)

Concentration (µg/mL)
1.4
1.2
1
0.8
0.6
0.4
0.2
0

Concentration (µg/mL)

PGT25·Cl
PAPMA·Cl
c
PGT100·TFA
PGT100·Cl
PGT75·TFA
PGT75·Cl
PGT50·TFA
PGT25·TFA
PGT50·Cl
PGT25·Cl
PAPMA·Cl

Figure 19. Broth microdilution results for all synthesized AMP mimics against (a) S.
aureus, (b) E. coli, and (c) P. aeruginosa, where decreased absorbance correlates to
increased bacterial death.
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Table 3
The minimum inhibitory concentration (MIC) determined from broth microdilution
testing in Mueller-Hinton broth for the most effective AMP mimics
MIC (µg/mL)
Polymer

S. aureus

E. coli

P. aeruginosa

1. (PAPMA·Cl)

1000

1000

1000

6. (PGT25·Cl)

-

-

1000

PAPMA·Cl demonstrated the greatest antimicrobial activity, providing 100% cell
death for all three of the bacteria evaluated within the therapeutic range. PAPMA·Cl’s
effectiveness against P. aeruginosa is of particular significance because of this bacteria’s
reported extreme resistance to traditional therapeutics.36 In general, antimicrobial activity
decreased with increasing GPMA content, and only the copolymer with the lowest
GPMA concentration (PGPMA25·Cl) showed 100% cell death within the therapeutic
range. Additionally, copolymers prepared with the TFA counterion showed lower
activity than those associated with the chloride counterion. This is attributed to the
greater coordination and bulk of the TFA counterion, which effectively shields the cation
and reduces interaction with the negatively charged bacterial membrane.
Recognizing that the measured MIC value depends on the testing conditions,
including media and broth type, buffer, and salt type and content,31 copolymer
effectiveness was also evaluated in low salt LB against E. coli and S. aureus. The results
of these tests are found in Table 4. In contrast to the findings observed in MHB, all
copolymers show MICs in the therapeutic range against S. aureus and E. coli when tested
in low salt LB. This suggests that the decrease in salt content allowed increased
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interaction of the AMPs with the bacterial membrane. All copolymers appear equally
effective against S. aureus, but the polymers with GPMA content greater than 75 mole %
show greater effectiveness against E. coli in the low salt environment, even when paired
with the TFA counterion. The increased effectiveness of GPMA rich polymers against E.
coli as opposed to APMA rich polymers, is attributed to mechanistic differences between
the guanidinium and primary amine moiety in bacterial cell death. The membrane
disrupting mechanism of APMA requires a critical concentration to sustain a hole in the
bacterial membrane and, thus, achieve MIC.32 The cell penetration mechanism of GPMA
requires fewer units to translocate across bacterial membranes.40
Table 4
The minimum inhibitory concentration (MIC) determined from broth microdilution
testing in low salt Luria broth
MIC (µg/mL)
Polymer

S. aureus

E. coli

1. (PAPMA·Cl)

300

300

2. (PGT25·TFA)

300

300

3. (PGT50·TFA)

300

300

4. (PGT75·TFA)

300

150

5. (PGT100·TFA)

300

70

Thus, these results indicate that incorporation of GPMA into APMA polymers
does not generally improve the antimicrobial activity. APMA rich polymers and
copolymers with chloride counterions show the most consistent antibacterial activity
against the broadest range of Gram-positive and Gram-negative bacteria. In a low salt
environment, however, GPMA rich copolymers demonstrate increased effectiveness
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against EC, which is attributed to mechanistic differences between guanidinium and
primary amine moieties.
Hemolysis Assay
Selectivity testing against red blood cells (RBCs) was performed for all polymers
at concentrations 50, 500, 1000 and 3000 µg/mL (Figure 20). Hemolysis testing
monitored the percent release of hemoglobin from RBCs as they lysed in comparison to a
positive and negative control. For all polymers, at all concentrations, RBC lysis is below
10%, indicating low eukaryotic toxicity at desired antimicrobial concentrations (~1000
µg/mL). In general, hemolysis increases with polymer concentration, and the GPMAcontaining polymers show greater hemolysis than the PAPMA homopolymer. Hemolysis
also increases with increasing GPMA content. This may be attributed to the lower
polarity of the GPMA molecule in comparison to the APMA molecule. No clear
differences are observed for the copolymers prepared with TFA vs Cl counterions.

% Hemolysis

10.0
8.0
6.0

50 µg/mL

4.0

500 µg/mL

2.0

1000 µg/mL
3000 µg/mL

0.0

Figure 20. Hemolysis testing, where % hemolysis of red blood cells as a function of
relevant antimicrobial concentrations is shown for all synthesized AMP mimics.

61

MTT Assay
The MTT assay utilized MCF-7 breast cancer cells as the representative
eukaryotic cell for selectivity testing. Figure 21 shows plots of % viability of MCF-7
cells as a function of polymer concentration after incubation for six hours (a) and 12
hours (b). After six hours, greater than 70% cell viability is demonstrated for solutions of
PAPMA homopolymer and PGT50 copolymers with both chloride and TFA counterions
at concentrations up to 2000 µg/mL. Exposure to the PGT homopolymers, however,
results in dramatically reduced cell viability. Similar results are observed after 12 hours
of incubation, however the PAPMA homopolymer display slightly higher cell viability
than the PGT50 copolymers. No clear difference is observed for polymers produced with
different counterions. As in the hemolysis testing, the increased eukaryotic cell death
caused by the GPMA polymers is attributed to their less polar character, in comparison to
that of the APMA molecule.
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a

% Cell Viability

100
80
PAPMA
60

PGT50·TFA
PGT100·TFA

40

PGT50·Cl

20

PGT·Cl

0
25

100
200
Concentration (µg/mL)

2000

b

% Cell Viability

100
80
PAPMA

60

PGT50·TFA
PGT100·TFA

40

PGT50·Cl
20

PGT100·Cl

0
25

100
200
Concentration (µg/mL)

2000

Figure 21. MTT Assay for select AMP mimics, where % cell viability of MCF-7 cancer
cells as a function of relevant antimicrobial concentrations is shown after incubation for
(a) 6 hrs and (b) 12 hrs.
Chapter Summary
GPMA was synthesized and polymerized with APMA via aqueous RAFT to produce
homopolymers and copolymers with narrow molecular weight distribution, DP of 30, and
desired copolymer composition. Antimicrobial activity was evaluated against Gram
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negative E. coli and P. aeruginosa and Gram positive S. aureus. Selectivity was
evaluated via hemolysis and MCF-7 cell viability testing. The PAPMA homopolymer
demonstrated the greatest antimicrobial activity and selectivity of the copolymers
evaluated, indicating its potential as a broad spectrum antibiotic. Effectiveness against P.
aeruginosa was particularly remarkable due to its resistance to traditional therapeutics.
Only copolymers with a low concentration of GPMA showed antimicrobial activity in
MHB, and GPMA copolymers with Cl counterion showed greater antimicrobial activity
than those with TFA counterion. When investigated in low salt LB, GPMA showed
equivalent effectiveness against S. aureus and greater effectiveness against E. coli in
comparison to that of APMA, demonstrating the salt sensitivity of the GPMA molecule.
Eukaryotic cell death increased with increasing GPMA content. Broad spectrum
antimicrobial activity and selectivity were demonstrated for fully water-soluble, primaryamine containing, methacrylamide polymers, without the need for incorporation of
guanadinium adducts. Evaluation of their effectiveness in preventing bacterial biofilm
formation is underway.
Recommendations for Future Work
Synthesis of APMA and GPMA polymers with lower molecular weights is
recommended. This will, hopefully, decrease the concentration of polymeric AMP
needed for complete cell death and allow for end groups investigation on antimicrobial
activity and selectivity for PAPMA·Cl. Namely, the effect of alkyl chains of varying
lengths added at the carboxylic terminal of the polymer will be analyzed to investigate
the hydrophobic impact of end groups on bacterial cell death. Also, decreased molecular
weight will, hopefully, allow PGT polymers to utilize the alternate bacterial cell death
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mechanism supported in low salt LB and other works. If effective antimicrobial activity
is achieved after decreasing the MW of PGT polymers, the tunability of APMA and
GPMA copolymers can then be better evaluated. If altering the molecular weight of PGT
polymers does not increase observed antimicrobial activity, incorporation of
hydrophobicity through copolymerization of GPMA with monomers that have pendant
aliphatic chains could be done to improve the hydrophilic/hydrophobic balance.
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CHAPTER VI
CONCLUSIONS
This work has utilized acrylamide based biomimetic polymers of specific
architectures to evaluate (1) the impact of specific saccharides of GM1 ganglioside on the
aggregation size and kinetics of Aβ monomers and (2) the antimicrobial activity and
selectivity of lysine and arginine functionalities. The key contributions from the first
section are as follows:
1. Synthesis of 2-(β-D-galactosyloxy)ethyl acrylamide (GalEAm) and 2-(β-Dglucosyloxy)ethyl acrylamide (GlcEAm) as novel glycomonomers with
attachment of the acrylamide backbone to the Cl’ carbon of the pendant
saccharide predominately in the β-orientation, increasing the biological relevance.
2. Polymerization of a series of GalEAm and GlcEAm homopolymers and
copolymers with DMA, via aRAFT, to form a novel glycopolymer platform that
has increased solubility and stability over a wide range of pH.
3. Determination of aggregation kinetics and aggregate size of Aβ in the presence of
glycopolymer. Low MW polymers of GalEAm and GlcEAm increased the lag
time of Aβ aggregation as compared to Aβ incubated without glycopolymers but
eventually resulted in highly aggregated species. High MW PGalEAm decreased
the lag time and hindered Aβ aggregation from proceeding past high MW
oligomers. High MW PGlcEAm increased the lag time and resulted in a mixture
of high MW oligomer, low MW oligomer and monomer. Low MW oligomer is
thought to be more toxic. Over all, the differences seen as a result of polymer
MW indicate that a concentration of saccharide greatly influences aggregation
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behavior. Additionally, the stereochemistry at the C4’ carbon, which is the
difference between glucose and galactose, results in aggregation of species
considered more toxic.
The key contributions from the second section include:
1. Improved synthesis of GPMA that allows for increased ease of production and
yield.
2. Expansion of our established acrylamide based antimicrobial peptide platform to
include an arginine mimic, GPMA, as well as a lysine mimic, APMA. Well
defined statistical copolymers of GPMA and APMA were polymerized via
aRAFT to enable investigation of antimicrobial activity and selectivity of GPMA
over a range of bacteria.
3. PAPMA demonstrated the best antimicrobial activity in MHB, effectively killing
E. coli, S. aureus, and P. aeruginosa which is particularly resistant to current
therapeutics. Only statistical copolymers with low incorporation of GPMA and
the Cl counterion were active in MHB. Use of low salt LB, showed that a high
presence of GPMA in copolymers increased activity against E. coli. Broth type
and counterion greatly impact GPMA due to the delocalization of charge across
the guanidinium moiety.
4. Selectivity testing against human red blood cells and cancer cells indicate that the
synthesized polymers do not harm eukaryotic cells within relevant therapeutic
concentrations. Polymers rich in GPMA were slightly more toxic due to
delocalization of charge across the guanidinium moiety.
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